Patents Assigned to Roche Palo Alto LLC
  • Publication number: 20190270713
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R1 and R8 are as defined herein.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 5, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Patent number: 10201525
    Abstract: A method of antagonizing P2X3 and/or P2X2/3 receptors or treating a disease misregulation of P2X3 and/or P2X2/3 receptors treating a patient with a compound of formula I wherein R1, R2, R3, R4, R5 and R6 are as defined herein, or a pharmaceutically acceptable salt thereof. wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: February 12, 2019
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Ronald Charles Hawley, Li Chen, Lichun Feng, Minmin Yang
  • Publication number: 20190016688
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 17, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20180319743
    Abstract: The applicaton discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R1R5, R6 and R7 are as defined herein.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Publication number: 20180318267
    Abstract: The object of the present invention is to inhibit oxidative metabolism of a compound of formula I by co-administration with ritonavir, a cytochrome P450 inhibitor.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Applicant: Roche Palo Alto LLC
    Inventor: Jonathan Q. TRAN
  • Publication number: 20180311240
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen BROKA, David Scott CARTER, Michael Patrick DILLON, Anthony P.D.W. FORD, Ronald Charles HAWLEY, Alam JAHANGIR, Amy Geraldine MOORE, Daniel Warren PARISH
  • Patent number: 10023589
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 17, 2018
    Assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Publication number: 20180141919
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: May 24, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 9896439
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted pyrazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: February 20, 2018
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Patent number: 9849136
    Abstract: A method for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: December 26, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Publication number: 20170247321
    Abstract: The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R1 R5, R6 and R7 are as defined herein.
    Type: Application
    Filed: May 17, 2017
    Publication date: August 31, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Publication number: 20170182057
    Abstract: A method for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein.
    Type: Application
    Filed: March 15, 2017
    Publication date: June 29, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Patent number: 9670151
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: June 6, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Publication number: 20170143672
    Abstract: A method of antagonizing P2X3 and/or P2X2/3 receptors or treating a disease misregulation of P2X3 and/or P2X2/3 receptors treating a patient with a compound of formula I wherein R1, R2, R3, R4, R5 and R6 are as defined herein, or a pharmaceutically acceptable salt thereof wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 25, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Ronald Charles Hawley, Li Chen, Lichun Feng, Minmin Yang
  • Patent number: 9643934
    Abstract: A method for preparing a compound of formula k or a salt or solvate thereof, wherein R1 is as defined herein, the method comprising treating a compound of formula j or a salt or solvate thereof, with ammonia, to form the compound of formula k.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: May 9, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Charles Alois Dvorak, Keena Lynn Green, Gary R. Lee
  • Publication number: 20170119739
    Abstract: The object of the present invention is to inhibit oxidative metabolism of a compound of formula I by co-administration with ritonavir, a cytochrome P450 inhibitor.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: Roche Palo Alto LLC
    Inventor: Jonathan Q. Tran
  • Patent number: 9617254
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: April 11, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Publication number: 20170096416
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted pyrazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Publication number: 20170096404
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20170081320
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
    Type: Application
    Filed: October 26, 2015
    Publication date: March 23, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Li Chen, Lichun Feng, Minmin Yang, Michael Patrick Dillon, Yingjie Lai